Well-documented on-target/off-tumour toxicities include B-cell aplasia after CD19 CAR-T therapy [41, 54, 57, 58] and rare fatal pulmonary events in early HER2-targeted CAR-T trials [58, 167]. Here, CD19 is linked to neoplasm.